We hypothesize that the alpha-specific PI3K inhibitor alpelisib could be the best drug with which to target the PI3K pathway in order to enhance the antitumor efficacy of anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer. Here, ERBB2 is linked to breast cancer.